Chieh Huang advises that consumer brands often face a binary outcome: become a huge business or fail completely. Therefore, founders shouldn't obsess over dilution from raising capital if it's the necessary fuel to unlock massive growth and avoid a $0 outcome.

The best time to raise money is when your company doesn't desperately need it. Approaching investors from a position of strength gives you leverage. If you wait until you're desperate, you will be forced to accept expensive, highly dilutive capital.

In cautious markets, biotech VCs aren't writing smaller checks; they are committing to larger rounds structured in tranches. This guarantees future capital if milestones are met, reducing financing risk. Founders must now present a comprehensive path to clinical proof of concept, not just a development candidate, to secure these large commitments.

Ron Najafi advises founders to accept investment when it's offered rather than over-negotiating valuation. The security of having capital on hand to navigate unforeseen challenges like clinical study hiccups is more critical for long-term survival than a marginal valuation increase.

By deliberately not over-raising, biotech startups preserve M&A optionality. A seemingly modest exit, like Surf Bio's $400M acquisition, can be a massive win for founders and early investors if the company remained lean, avoiding the need for a billion-dollar outcome.

Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

Financing discussions should carry the same strategic weight as M&A talks. Philip Ross argues the cost of capital from selling stock is often theoretically higher than from selling the entire company. This reframes the decision to dilute ownership for funding as a pivotal choice that boards and management teams should not take lightly.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.